Please login to the form below

Not currently logged in
Email:
Password:

Abbott and Seattle expand antibody-drug conjugate collaboration

Pharma company could pay $220m per oncology target

Abbott headquarters

Abbott has expanded its antibody-drug conjugate (ADC) collaboration with Seattle Genetics and will now use the technology in a number of extra types of cancer.

This latest agreement builds upon an original $8m deal made in March, 2011, for Abbott to use Seattle's ADC technology with antibodies for one target in oncology, and means the big pharma company can now use this technology in additional oncology targets.

In return, Seattle will receive an upfront fee of $25m, as well as up to $220m in milestone payments per target, but the company declined to specify how many oncology targets were in development, and in what cancer indications they were in.

The expanded deal follows a number of encouraging developments in the area of ADCs, which comprise a cancer cell-targeting antibody that is attached to a cytotoxic drug via a linking technology, allowing tumour cells to be targeted more directly over healthy cells.

These successes include Seattle's own Adcetris (brentuximab vedotin), which was approved in the US last year to treat Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, achieving revenues of $34.5m in the first quarter of 2012.

There has also been great excitement recently about Roche's T-DM1, which demonstrated “outstanding” phase III results in the treatment of breast cancer.

“ADCs have emerged as an important therapeutic approach to cancer, driven by the FDA approval of Adcetris, and encouraging data from numerous clinical and preclinical ADC programmes in development by Seattle Genetics and our collaborators,” said Natasha Hernday, VP, corporate development at Seattle Genetics.

“We are leading the field in ADC development, and this expanded collaboration with Abbott further validates our technology and approach in targeting and treating cancer.”

This latest deal will see Abbott take responsibility for research, product development, manufacturing and commercialisation of any ADC products as part of the collaboration. The US pharma firm will also provide Seattle with annual maintenance fees and research support payments.

24th October 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
WE Communications

WE’s global and European healthcare hub is based in London, and works with experienced teams across the globe; teams encompassing...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics